secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001104659-25-054628
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 5.02, 2.01, 3.01, 3.03, 5.03, 5.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics completes acquisition by Sun Pharma for $4.10/share plus CVR
--------------------------------------------------------------------------------

- Merger closed May 30, 2025; Checkpoint becomes wholly owned subsidiary of Sun Pharma.
- Shareholders receive $4.10 cash per share plus non-tradable CVR (up to $0.70 contingent on EU regulatory milestones for cosibelimab).
- Common stock delisted from Nasdaq; Company intends to suspend SEC reporting obligations.
- All prior directors and officers resigned; Abhay Gandhi (President), Sudhir Valia (Director), Zvi Albert (CFO) appointed from Sun Pharma.
- Founders Agreement, Management Services Agreement, Board Advisory Services Agreement terminated at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/tm2516558d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-054628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer